Search Results

Displaying Results 251-275 of 389 "'IO'"

Jan 27, 2026, 05:00 ET Blockchain for Good Alliance (BGA) and FLock.io Enter Strategic Partnership to Advance "Blockchain and AI for Good"

https://x.com/flock_io LinkedIn: https://www.linkedin.com/company/flock-io

More news about: Blockchain for Good Alliance (BGA)

Jan 22, 2026, 09:55 ET Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

parallel.Woori IO emphasized that the FDA's clarification allows the Company to decouple early commercialization from longer medical-device approval timelines without compromising scientific rigor or future regulatory objectives. By launching first in the consumer wellness category, Woori IO aims to accelerate

More news about: OSR Holdings

Jan 22, 2026, 00:00 ET TUMI PRESENTA LA NUOVA GENERAZIONE DELLA COLLEZIONE TUMI ALPHA CON CAMPAGNE IN CUI SONO PRESENTI LANDO NORRIS E WEI DAXUN

decisione."Quando ti prepari per qualcosa di importante, non vuoi distrazioni – vuoi che tutto funzioni esattamente come dovrebbe", commenta Norris. "Che io stia gareggiando o semplicemente in movimento, l'importante è essere pronti. E ti accorgi che Alpha è fatta per questo modo di pensare".La stessa

More news about: Tumi, Inc.

Jan 16, 2026, 06:59 ET Mantle to Introduce New RWA Trading Capabilities and Sports Fan Economies with Fluxion, VOOI, SCOR in Upcoming Jan Livestream

https://app.vooi.io X: https://x.com/vooi_io Telegram: https://t.me/vooi_appAbout FluxionFluxion

More news about: Mantle

Jan 16, 2026, 06:51 ET Mantle to Introduce New RWA Trading Capabilities and Sports Fan Economies with Fluxion, VOOI, SCOR in Upcoming Jan Livestream

https://app.vooi.io X: https://x.com/vooi_io Telegram: https://t.me/vooi_appAbout FluxionFluxion

More news about: Mantle

Jan 15, 2026, 20:00 ET Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs

(B7-H3 × PD-L1 bispecific ADC): ATG-125 is an "IO+ADC " dual-function molecule targeting B7-H3 and PD-L1, integrating the direct cytotoxic activity of an ADC with the durable immune activation of immuno-oncology (IO) therapies. By simultaneously blocking B7-H3- and

More news about: Antengene Corporation Limited

Jan 15, 2026, 04:30 ET Il Comune di Genova sceglie Appian per digitalizzare e modernizzare i propri processi

settore scolastico, è stato il primo ambito digitalizzato nel Comune, con servizi già online come il fascicolo del cittadino e il sotto fascicolo "io-genitore" per la gestione dei servizi scolastici. Il sistema educativo, fiore all'occhiello dell'amministrazione, verrà rivisitato in maniera integrata per

More news about: Appian

Jan 12, 2026, 08:00 ET Novita Pharmaceuticals Announces FDA Orphan Drug Designation Granted to NP-G2-044 for the Treatment of Pancreatic Cancer

specifically targeting metastasis. Furthermore, while Immuno-Oncology (IO) therapies, particularly immune checkpoint inhibitors, have made significant strides in cancer treatment, a large proportion of patients do not respond to existing IO treatments. Novita aims to address both of these critical medical

More news about: Novita Pharmaceuticals, Inc.

Jan 08, 2026, 06:29 ET European deep-tech company Willo emerges from stealth with demonstration of alignment-free wireless power

https://ces26.mapyourshow.com/8_0/exhibitor/exhibitor-details.cfm?exhid=001Pp000013iO7eIAE.

More news about: Willo Technologies

Jan 05, 2026, 18:07 ET Macronix Flash Memory Family Includes Highest Level of Automotive Safety

kinds of multi-I/O interfaces, giving designers broader flexibility in product development. The OctaFlash™ MX25/66_UM/LM/UW/LW series features the x8IO interface, whereas the QSPI MX25/66/U/L_G series uses a Quad I/O interface. The family's array of additional features includes:3V

More news about: Macronix

Dec 25, 2025, 03:45 ET China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval

(pCR) rates and enabled most patients to avoid the burden of postoperative adjuvant chemotherapy.This therapy is the first and only dual-IO regimen approved globally for neoadjuvant treatment of colon cancer[i], filling a critical gap in neoadjuvant

More news about: Innovent Biologics

Dec 19, 2025, 11:50 ET Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings

of Woori IO Co., Ltd. ("Woori IO"), a leading Korean medical device innovator in noninvasive glucose monitoring technology, approved a share exchange at an Extraordinary General Meeting ("EGM") held at Woori IO's headquarters in Jeonju, Korea. The approved share exchange will result in Woori IO becoming

More news about: OSR Holdings Inc.

Dec 18, 2025, 08:00 ET StackGen Named in Four Gartner® Hype Cycles™ for Platform Engineering, Infrastructure Strategy, Site Reliability Engineering, and I&O Automation in 2025

multimedia:https://www.prnewswire.com/news-releases/stackgen-named-in-four-gartner-hype-cycles-for-platform-engineering-infrastructure-strategy-site-reliability-engineering-and-io-automation-in-2025-302645715.htmlSOURCE

More news about: StackGen

Dec 16, 2025, 09:05 ET Vectorize Breaks 90% on LongMemEval with Open-Source AI Agent Memory System

https://github.com/vectorize-io/hindsight.The full research paper is available on arXiv at:

More news about: Vectorize AI, Inc.

Dec 15, 2025, 09:00 ET Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research

Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programsSEOUL, South Korea, Dec. 15, 2025 /PRNewswire/

More news about: Lunit

Dec 12, 2025, 09:32 ET Ultra Pure, LLC Achieves SQF Certification, Strengthening Its Position as a Leader in the Industrial Alcohol Market

https://www.youtube.com/watch?v=Io1IAvHVQ_MCheck out the NPR planet Money Episode 826 "The Vodka Proof"

More news about: Ultra Pure, LLC

Dec 11, 2025, 08:00 ET HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025

exclusively to immuno-oncology science, distinct from the broader ESMO Annual Congress. While the annual ESMO meeting spans all oncology disciplines, ESMO-IO focuses on immune mechanisms, translational innovation, and next-generation therapeutic strategies across innate and adaptive immunity.Presentation

More news about: HanchorBio Inc.

Dec 11, 2025, 00:50 ET 新橋生物公佈 Ragistomig 1期劑量拓展研究數據：療效可比，安全性顯著提升

馬里蘭州羅克維爾2025年12月11日 /美通社/ -- 12月11日，全球生物科技平台公司新橋生物（NovaBridge Biosciences；納斯達克股票代碼：NBP，下稱「新橋生物」或「公司」）在2025年歐洲腫瘤內科學會免疫腫瘤學大會（ESMO-IO 2025）上，以海報形式公佈了其與韓國公司ABL Bio共同開發的4-1BB × PD-L1雙特異性抗體ragistomig，在3毫克/千克劑量下每6週一次（Q6W）延長給藥間隔方案的1期研究最新數據。該海報摘要編號#688，由HealthONE

More news about: 新橋生物

Dec 10, 2025, 20:53 ET Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025

advanced unresectable or metastatic triple-negative breast cancer (TNBC) at the 2025 European Society for Medical Oncology Immuno-Oncology Congress (ESMO IO) in London, UK. Based on positive efficacy and safety profile, the ivonescimab combination therapy for first-line TNBC was previously included

More news about: Akeso, Inc.

Dec 09, 2025, 08:14 ET Sands China Celebrates 10th Anniversary of Local SME Supplier Support Programme and Hosts Supplier Excellence Awards

Investment Promotion Institute of the Macao Special Administrative Region; Paulo Coutinho, director and editor-in-chief of Macau Daily Times; and Lam Io Meng, deputy general manager of Macao Daily News.Following the ceremony, a group of local enterprises joined a cocktail and business networking

More news about: Sands China Ltd.

Dec 08, 2025, 07:00 ET iyO Secures Trademark Victory: Restraining Order Against Sam Altman, Jony Ive, and OpenAI Upheld

conflicting "IO" mark, validating iyO's claims of trademark infringement.SAN FRANCISCO, Dec. 8, 2025 /PRNewswire/ -- iyO, Inc., the pioneer in natural language computing, today announced a decisive legal victory against IO Products,

More news about: iyO, Inc.

Dec 04, 2025, 18:38 ET Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies

October 22, 2025, aims to accelerate the global development and commercialization of Innovent's next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, including the global partnership on IBI363 (PD-1/IL-2α-bias) and IBI343 (CLDN18.2 ADC), and

More news about: Innovent Biologics

Dec 04, 2025, 17:31 ET Basal Cell Carcinoma Market Poised for Steady Growth Throughout Forecast Period (2025-2034) Driven by Novel Drug Approvals and Expanding Patient Pool | DelveInsight

non-clinical stage products, and the key BCC companies, including PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf

More news about: DelveInsight Business Research, LLP

Dec 04, 2025, 08:13 ET 新橋生物宣佈將在ESMO-IO大會上公佈Ragistomig擴展性1期臨床數據

2025年12月4日 /美通社/ -- 全球生物科技平台公司新橋生物（NovaBridge Biosciences；納斯達克股票代碼：NBP，下稱「新橋生物」或「公司」）宣佈，其與韓國公司ABL Bio共同開發的4-1BB × PD-L1雙特異性抗體ragistomig，其擴展性1期給藥研究新數據將在2025年歐洲腫瘤內科學會免疫腫瘤學大會（ESMO-IO 2025）上以海報形式公佈。該海報摘要編號#688，屆時將由HealthONE Denver旗下Sarah Cannon研究所（SCRI）主任Gerald Falchook博士進行展示。新橋生物首席醫學官Phillip